Company intelligence

ETON

Eton Pharmaceuticals, Inc. · NASDAQ · Healthcare

Price$61.54-2.40% · −$1.51

Market cap1.69BEquity value

P / E133.8Trailing ratio

Volume183.77KLatest session

Market data

ETON price chart

TradingView

Related signals

1 min delayed

Browse public ETON signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ETONFeb 25, 2026-2.40% since signal

Eton's DESMODA Launch Signals Major Growth Opportunity in Rare Disease Market

Eton Pharmaceuticals has announced the FDA approval of DESMODA, an oral solution for central diabetes insipidus, set to launch on March 9, 2026. This innovative medication introduces precise dosing for patients and is projected to generate peak sales between $30-50 million annually, marking a significant growth opportunity for Eton in the rare disease market.

View signal analysis

ETONMay 29, 2025-0.84% since signal

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

FDA approved Eton's Khindivi for pediatric adrenal insufficiency treatment. Khindivi offers an easy-to-use hydrocortisone oral solution for patients aged 5+. Eton predicts revenues of $28 million by 2030, growing from $3 million in 2025. Analyst maintains Buy rating, raising price target for ETON stock to $35.

View signal analysis

Research